Intezyne offers a new solution to oncologists, who must balance the anti-tumor activity of best-in-class chemotherapeutics with their severe toxicities. Drawing from their expertise in polymer chemistry, the Company's founders created the IVECT Method to limit chemotherapeutics' anti-tumor activity to within the tumor itself, thereby sparing healthy tissues. Ultimately, the IVECT Method has demonstrated preclinical proof-of-concept in a number of therapeutic and diagnostic categories, giving the Company the opportunity to monetize this asset through licensing agreements outside of Intezyne's primary oncology focus.

THE IVECT METHOD

Intezyne's IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy. The key to this breakthrough technology is the Company's multi-disciplinary approach, integrating polymer physics and materials science with organic chemistry, polymer chemistry, biochemistry, and biology. Intezyne can improve patient outcomes significantly by amplifying the efficacy and safety profiles of best-in-class cancer drugs, whose potency often is handicapped by nonspecific delivery outside of the tumor site, requiring higher dosing and resulting in severe toxicities. The IVECT Method has proven to be extraordinarily versatile, in terms of the diversity of materials that can be encapsulated securely, and its unique modular design confers unmatched adaptability at a minimal cost. Beyond chemotherapy, the Company has proven the IVECT Method can deliver many classes of small molecules, in addition to nucleic acids, oligopeptides, and diagnostic imaging agents.

Intezyne currently has four cancer chemotherapeutics in its pipeline: two lead programs in final preparation for IND submission and two others in earlier stages of preclinical development.

The Company's lead program, IT-141, has shown significant activity against a diverse number of cancer cell lines. Advanced preclinical studies showed IT-141 is extremely well tolerated, and significantly outperforms Pfizer's Camptosar (irinotecan), which shares the same active component. Intezyne plans to file an IND for IT-141 for the treatment of metastatic colorectal cancer.

IT-143, Intezyne's drug encapsulating doxorubicin, is being evaluated for treatment of small cell lung cancer, cancer of the head and neck, and breast cancer. In addition to being well tolerated, IT-143 demonstrated superior pharmacokinetics versus free doxorubicin and its current formulations. Advanced preclinical studies currently are underway and will conclude this year.

Intezyne is gaining new ground in the area of tumor-specific gene therapy. The Company's IT-121 program is in early preclinical testing and thus far has demonstrated target gene expression far superior to that of commercially available gene transfection systems. Unlike other gene therapy programs, IT-121 minimizes accumulation in the liver.

BUSINESS STRATEGY

Intezyne is treating cancer better. As the Company presents and publishes its results, it expects the pharmaceutical industry will take notice. Beyond oncology, Intezyne has demonstrated the IVECT Method is applicable in multiple therapeutic and diagnostic areas, and management will entertain offers for partnerships and licensure. Intezyne intends to retain manufacturing rights whenever possible.

In 2007, Intezyne raised $5 million in a Series A financing, for a valuation of $14 million, and the Company currently is seeking to raise $20 million. This financing will fund the advancement of Intezyne's lead product candidates through two Phase 1 studies and support IT-141 through Phase 2 clinical development.

INTELLECTUAL PROPERTY ESTATE

Multiple dimensions of Intezyne's revolutionary technology are protected by broad patent application families, pending in the United States and internationally. All patents are wholly owned by Intezyne.

LEADERSHIP

Intezyne's team of Ph.D. scientists is supported by five active, yet independent, directors with backgrounds in finance, biotechnology, and product development. Additionally the Company's Scientific Advisory Board, with their clinical experience and expertise in the fields of cancer biology, polymer synthesis, polymer physics, and analytical chemistry, provides regular insight and guidance for Intezyne's product development activities.

Intezyne was cofounded in 2004 by Habib Skaff, Ph.D., a synthetic chemist specializing in nanotechnology, and Kevin Sill, Ph.D., a synthetic polymer chemist, who have more than 21 peer-reviewed articles and 35 patents between them. Intezyne also benefits from Chief Financial Officer Micheal Cole's 30 years of healthcare finance experience.